Generation Bio is developing a breakthrough class of genetic medicines based on its proprietary GeneWave technology Founded by Mark D. Angelino and Robert Kotin in 2016, Generation Bio is backed by investors that include T. Rowe Price, Deerfield, Foresite Capital, Atlas Venture, and Fidelity and is headquartered in Cambridge.